Gene-defective amycolatopsis mediterranei as well as construction method and application thereof
By constructing a genetically defective Mediterranean pseudo-amylopectin bacterium, the problem of finding a suitable strain for the biosynthetic gene cluster of pseudo-amylopectin bacterium was solved, enabling the effective activation of the biosynthetic gene cluster of pseudo-amylopectin bacterium and the efficient synthesis of natural products.
Patent Information
- Application Number
- CN202411588286.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-08
- Publication Date
- 2026-05-08
AI Technical Summary
Existing technologies struggle to provide suitable chassis strains for the mining of biosynthetic gene clusters in pseudoamycetes, as common Streptomyces chassis cells are unsuitable for the mining of biosynthetic gene clusters in pseudoamycetes.
Genetically defective Mediterranean amylopectin strains were constructed by knocking out its rifamycin biosynthesis gene cluster and FnCas12a encoding gene, and then deleting related gene clusters and integration plasmids using the CRISPR/Cas system or homologous recombination method to form gene-defective strains suitable as chassis strains.
A chassis strain suitable for the mining of biosynthetic gene clusters in pseudoamycetes is provided, which can effectively activate and mine unidentified biosynthetic gene clusters, thereby enhancing the synthetic potential of natural products.
Smart Images

Figure CN121991994A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to genetically defective Mediterranean pseudoamycetes, their construction methods, and applications, and relates to the field of microbial technology. Background Technology
[0002] Microbial genomes contain a vast number of gene clusters for the biosynthesis of natural products, but the functions of the vast majority of these genes remain unidentified and are in a "silent" state. Their encoded products are referred to as microbial "dark matter of life." The biosynthesis process of microbial natural products is intricate and greatly influenced by both internal and environmental factors. How to effectively activate and mine this microbial "dark matter of life" has always been a bottleneck limiting the discovery of new natural products and a challenge in this field.
[0003] Actinomycetes have always been a major source of microbial drugs. Among them, *Amycolatopsis* is a rare actinomycete, initially classified under the genus *Sreptomyces*, then *Nocardia*, and finally reclassified into a new genus (*Amycolatopsis*), indicating a unique "position" in evolutionary history. Currently, fewer than 100 species have been published, but their natural products have very high pharmaceutical value and play crucial roles in clinical practice. Examples include the glycopeptide antibiotics vancomycin and orivantoxin (a derivative of the vancomycin analog chloroeremomycin), and the ansaxa antibiotic rifamycin. In addition to these three clinical antibiotics, strains of this genus synthesize more than 160 other natural products with antibacterial, cytotoxic, and antioxidant activities. Furthermore, large-scale genome sequencing and functional annotation analysis show that strains of this genus encode a large number and diverse gene clusters with low homology compared to those identified in databases, suggesting that most of their encoded products are novel, unidentified compounds. Therefore, gene cluster function identification and analysis of *Amycium* strains is one of the hot topics in this field.
[0004] Several methods for activating gene clusters have been reported, mainly including two strategies: those based on natural hosts and those based on heterologous hosts. Developing efficient gene operating systems in natural hosts is beneficial for reshaping the transcriptional regulatory circuits of target gene clusters to achieve activation. However, considering that gene operating system development varies from strain to strain, is time-consuming, and often futile, activation strategies based on natural hosts are generally not suitable for tapping the natural product production potential of most microorganisms, and are even less suitable for gene cluster mining in the genomes of uncultured microorganisms.
[0005] Cloning and heterologous expression of gene clusters is considered a commonly used strategy for activating silent gene clusters. This heterologous host-based strategy is more flexible and can be applied to gene cluster resources from culturable microorganisms as well as microorganisms not yet cultured in the laboratory. The main steps of this strategy include: 1) cloning (or reconstructing) the target gene cluster from the microbial genomic DNA; 2) heterologous expression in host / chassis cells with a relatively mature operating system (such as *Streptomyces cerevisiae*, *Escherichia coli*, etc.); and 3) analyzing the chemical composition and determining the structure of the heterologous expression product. Among these steps, the heterologous host / chassis cell is crucial for activating silent gene clusters. A good chassis cell can provide a clean metabolic background, which is beneficial for the subsequent isolation and purification of expressed compounds.
[0006] When mining gene cluster resources from actinomycetes, Streptomyces chassis cells are generally given priority. For example, Streptomyces coelicolor derivatives (CH999, M1154, etc.), Streptomyces albus (J1074, Del14, etc.), and Streptomyces avermitilis derivatives (SUKA5, SUKA22, etc.) have many successful examples of expressing known or unknown gene clusters. Given the unique evolutionary position of Amylopectinobacteria, common Streptomyces chassis cells may not be suitable for mining biosynthetic gene clusters derived from Amylopectinobacteria. Therefore, providing a chassis strain suitable for mining biosynthetic gene clusters from Amylopectinobacteria is a pressing technical problem that needs to be solved in this field. Summary of the Invention
[0007] This invention provides a genetically defective Mediterranean pseudoamycete and its construction method, which serves as a chassis strain suitable for the discovery of biosynthetic gene clusters in pseudoamycete bacteria.
[0008] This invention also provides the application of the aforementioned gene-deficient Mediterranean pseudoamycetes in the mining of actinomycete biosynthetic gene clusters and the synthesis of natural products.
[0009] The first aspect of this invention provides a method for constructing a genetically defective Mediterranean pseudo-amylopectin bacterium, comprising the following steps:
[0010] Knock out the rifamycin biosynthesis gene cluster and the integration plasmid pDZLCas12a containing the FnCas12a encoding gene from the genome of the receptor *Amycium thalianae* U32 (Cas12a) to obtain *Amycium thalianae* with the aforementioned gene defect.
[0011] In one specific embodiment, the rifamycin biosynthesis gene cluster includes 43 genes: rifS, rifT, rif35, rif0, rifA, rifB, rifC, rifD, rifE, rifF, rif1, rifG, rifH, rifI, rifK, rifL, rifM, rifN, rifO, rif2, rifP, rifQ, rif3, rif4, rif5, rif6, rif7, rif8, rif9, rif10, rif11, rif17, rif18, rif19, rif20, rifR, rif13, rif14, rif15A, rif15B, rif16, rifJ, and rif36.
[0012] The nucleotide sequence of the rifS is the sequence numbered AMED_0613 in Genebank CP002000;
[0013] The nucleotide sequence of the rifT is the sequence numbered AMED_0614 in Genebank CP002000;
[0014] The nucleotide sequence of rif35 is the sequence numbered AMED_0615 in Genebank CP002000;
[0015] The nucleotide sequence of rif0 is the sequence numbered AMED_0616 in Genebank CP002000;
[0016] The nucleotide sequence of rifA is the sequence numbered AMED_0617 in Genebank CP002000;
[0017] The nucleotide sequence of rifB is the sequence numbered AMED_0618 in Genebank CP002000;
[0018] The nucleotide sequence of rifC is the sequence numbered AMED_0619 in Genebank CP002000;
[0019] The nucleotide sequence of rifD is the sequence numbered AMED_0620 in Genebank CP002000;
[0020] The nucleotide sequence of the rifE is the sequence numbered AMED_0621 in Genebank CP002000;
[0021] The nucleotide sequence of the rifF is the sequence numbered AMED_0622 in Genebank CP002000;
[0022] The nucleotide sequence of rif1 is the sequence numbered AMED_0623 in Genebank CP002000;
[0023] The nucleotide sequence of rifG is the sequence numbered AMED_0624 in Genebank CP002000;
[0024] The nucleotide sequence of the rifH is the sequence numbered AMED_0625 in Genebank CP002000;
[0025] The nucleotide sequence of the rifI is the sequence numbered AMED_0626 in Genebank CP002000;
[0026] The nucleotide sequence of rifK is the sequence numbered AMED_0627 in Genebank CP002000;
[0027] The nucleotide sequence of the rifL is the sequence numbered AMED_0628 in Genebank CP002000;
[0028] The nucleotide sequence of rifM is the sequence numbered AMED_0629 in Genebank CP002000;
[0029] The nucleotide sequence of the rifN is the sequence numbered AMED_0630 in Genebank CP002000;
[0030] The nucleotide sequence of the rifO is the sequence numbered AMED_0631 in Genebank CP002000;
[0031] The nucleotide sequence of rif2 is the sequence numbered AMED_0632 in Genebank CP002000;
[0032] The nucleotide sequence of the rifP is the sequence numbered AMED_0633 in Genebank CP002000;
[0033] The nucleotide sequence of the rifQ is the sequence numbered AMED_0634 in Genebank CP002000;
[0034] The nucleotide sequence of the rif3 is the sequence numbered AMED_0635 in Genebank CP002000;
[0035] The nucleotide sequence of the rif4 is the sequence numbered AMED_0636 in Genebank CP002000;
[0036] The nucleotide sequence of the rif5 is the sequence numbered AMED_0637 in Genebank CP002000;
[0037] The nucleotide sequence of rif6 is the sequence numbered AMED_0638 in Genebank CP002000;
[0038] The nucleotide sequence of the rif7 is the sequence numbered AMED_0639 in Genebank CP002000;
[0039] The nucleotide sequence of the rif8 is the sequence numbered AMED_0640 in Genebank CP002000;
[0040] The nucleotide sequence of the rif9 is the sequence numbered AMED_0641 in Genebank CP002000;
[0041] The nucleotide sequence of rif10 is the sequence numbered AMED_0642 in Genebank CP002000;
[0042] The nucleotide sequence of rif11 is the sequence numbered AMED_0643 in Genebank CP002000;
[0043] The nucleotide sequence of rif17 is the sequence numbered AMED_0644 in Genebank CP002000;
[0044] The nucleotide sequence of rif18 is the sequence numbered AMED_0645 in Genebank CP002000;
[0045] The nucleotide sequence of rif19 is the sequence numbered AMED_0646 in Genebank CP002000;
[0046] The nucleotide sequence of rif20 is the sequence numbered AMED_0647 in Genebank CP002000;
[0047] The nucleotide sequence of the rifR is the sequence numbered AMED_0648 in Genebank CP002000;
[0048] The nucleotide sequence of rif13 is the sequence numbered AMED_0649 in Genebank CP002000;
[0049] The nucleotide sequence of rif14 is the sequence numbered AMED_0650 in Genebank CP002000;
[0050] The nucleotide sequence of rif15A is the sequence numbered AMED_0651 in Genebank CP002000;
[0051] The nucleotide sequence of rif15B is the sequence numbered AMED_0652 in Genebank CP002000;
[0052] The nucleotide sequence of rif16 is the sequence numbered AMED_0653 in Genebank CP002000;
[0053] The nucleotide sequence of rifJ is the sequence numbered AMED_0654 in Genebank CP002000;
[0054] The nucleotide sequence of rif36 is the sequence numbered AMED_0655 in Genebank CP002000.
[0055] In one specific embodiment, the FnCas12a encoding gene is the Cpf1 gene sequence in Genebank No. MF193599, the protein sequence is the sequence in Genebank No. ASK09413.1, and the integration site of the FnCas12a encoding gene is located inside the gene numbered AMED_0846 in Genebank No. CP002000.
[0056] In one specific implementation, the rifamycin biosynthesis gene cluster and the integration plasmid pDZLCas12a containing the FnCas12a coding gene in *Amylopectinus thaliana* U32 (Cas12a) can be knocked out using the CRISPR / Cas system, or the rifamycin biosynthesis gene cluster and the integration plasmid pDZLCas12a containing the FnCas12a coding gene in *Amylopectinus thaliana* U32 (Cas12a) can be deleted using conventional homologous recombination.
[0057] Furthermore, the rifamycin biosynthesis gene cluster in *Amycium thalianae* U32 (Cas12a) and the integrative plasmid pDZLCas12a containing the FnCas12a coding gene can be knocked out using the CRISPR / Cas12a system. Specifically, the rifamycin biosynthesis gene cluster is knocked out by constructing a knockout vector that knocks out the rifamycin biosynthesis gene cluster in the genome of the recipient *Amycium thalianae* U32 (Cas12a), and the integrative plasmid pDZLCas12a is knocked out by constructing a knockout vector that knocks out the integrative plasmid pDZLCas12a containing the FnCas12a coding gene.
[0058] Specifically, the knockout vector for the rifamycin biosynthesis gene cluster is named pULcrRNA-UDrif-crRNArif. It is constructed by inserting the upstream and downstream homologous arms of the rifamycin biosynthesis gene cluster into the NdeI restriction site of the pULcrRNA vector as a repair template; and by inserting the oligonucleotide chains corresponding to the crRNAs targeting the upstream and downstream boundaries of the rifamycin biosynthesis gene cluster between the BpiI and AseI restriction sites. The oligonucleotide chains corresponding to the crRNAs targeting the upstream boundary of the rifamycin biosynthesis gene cluster are Urif-crRNA-1 and Urif-crRNA-2, and the oligonucleotide chains corresponding to the crRNAs targeting the downstream boundary of the rifamycin biosynthesis gene cluster are Drif-crRNA-1 and Drif-crRNA-2.
[0059] Specifically, the knockout vector of the integration plasmid pDZLCas12a containing the FnCas12a encoding gene is named pULcrRNA-UDcas12a-crRNAcas12a. It is obtained by inserting the DNA recombination repair homologous arm into the NdeⅠ restriction site of the pULcrRNA vector and inserting the oligonucleotide chain corresponding to the crRNA targeting the FnCas12a encoding gene between the BpiⅠ and AseⅠ restriction sites. The oligonucleotide chains corresponding to the crRNA targeting the FnCas12a encoding gene are pRT803crRNA-F and pRT803crRNA-R.
[0060] A second aspect of the present invention provides a genetically defective Mediterranean pseudoamycete bacterium constructed according to any of the methods described above.
[0061] The third aspect of this invention provides the application of the aforementioned gene-deficient Mediterranean pseudoamycetes as a chassis strain in the mining of actinomycete biosynthetic gene clusters and / or the biosynthesis of natural products.
[0062] A fourth aspect of the present invention provides a method for identifying biosynthetic gene clusters in actinomycetes, comprising the following steps:
[0063] The target gene cluster derived from the target actinomycete was introduced into the gene-deficient Mediterranean pseudoamycetes, and heterologous expression was performed in the gene-deficient Mediterranean pseudoamycetes. The heterologous expression product was then analyzed and its structure determined.
[0064] In one specific embodiment, the target actinomycete is at least one of the genera *Amycium*, *Saccharomyces*, *Micromonospora*, and *Streptomyces*.
[0065] The fifth aspect of this invention provides a method for heterologous synthesis of a target compound derived from actinomycetes, comprising:
[0066] The target compound biosynthesis gene cluster derived from actinomycetes was introduced into the gene-deficient Mediterranean pseudoamycetes, heterologously expressed in the gene-deficient Mediterranean pseudoamycetes, and the target compound was isolated from the culture product of the gene-deficient Mediterranean pseudoamycetes.
[0067] A sixth aspect of the present invention provides a biomaterial, said biomaterial being selected from any of the following:
[0068] 1) A knockout vector for the rifamycin biosynthesis gene cluster in the genome of the recipient *Amylopectinus thaliana* U32 (Cas12a);
[0069] 2) Knockout vector of the integration plasmid pDZLCas12a containing the FnCas12a encoding gene in the genome of the receptor Amylopectinus thaliana U32 (Cas12a).
[0070] This invention constructs a genetically defective Mediterranean amylopectin bacterium by knocking out the rifamycin biosynthesis gene cluster in the genome of Mediterranean amylopectin U32 (Cas12a) and the integration plasmid pDZLCas12a containing the FnCas12a encoding gene. This amylopectin can be used as a chassis strain and as a heterologous expression host for mining identified or unidentified biosynthesis gene clusters in amylopectin bacterium or similar species. Attached Figure Description
[0071] Figure 1 PCR validation results for U32Δrif, a basal cell of *Amycium thaliana*.
[0072] Figure 2 The results of comparing the HPLC chromatograms of the chassis cells U32Δrif of *Acidithiomycium thuringiensis* with the fermentation broth of its originating strain. Detailed Implementation
[0073] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions in the embodiments of this invention will be clearly and completely described below in conjunction with the embodiments of this invention. Obviously, the described embodiments are only some embodiments of this invention, not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.
[0074] The receptor *Amycolatopsis mediterranei* U32 (Cas12a) and pULcrRNA vector used in the following examples are described in the literature: Zhou Y, Liu X, Wu J, Zhao G and Wang J (2020) CRISPR-Cas12a-Assisted Genome Editing in *Amycolatopsis mediterranei*. Front. Bioeng. Biotechnol. 8:698. doi:10.3389 / fbioe.2020.00698. The above biological materials are available to the public from the applicant.
[0075] The nucleotide sequences of the primers or oligonucleotide chains used in the following examples are shown in Table 1.
[0076] Table 1. Nucleotide sequences of primers or oligonucleotide chains used in the embodiments of the present invention.
[0077]
[0078]
[0079] Example 1: Construction of a gene-deficient Mediterranean pseudo-amylopectin bacterium
[0080] Step 1: Construction of the rifamycin biosynthesis gene cluster knockout vector
[0081] Based on the boundaries of the rifamycin biosynthesis gene cluster (rif, Genebank ID CP002000 AMED_0613-AMED_0655) in the receptor *Amycium thalianae* U32 (Cas12a), primers were designed to amplify the upstream homologous arm (Urif) and the downstream homologous arm (Drif). Primers for amplifying the upstream homologous arm included Urif-F and Urif-R, and primers for amplifying the downstream homologous arm included Drif-F and Drif-R. Their nucleotide sequences are shown in Table 1. Based on the designed upstream and downstream homologous arm primers, PCR amplification was performed using the *Amycium thalianae* U32 (Cas12a) genome as a template. The PCR product was then assembled into the NdeⅠ site of the vector pULcrRNA via homologous recombination to obtain the recombinant vector, named pULcrRNA-UDrif.
[0082] After annealing, the oligonucleotide chains (Urif-crRNA-1 / -2, Drif-crRNA-1 / -2) corresponding to the crRNAs targeting the upstream and downstream boundaries of the rif were cloned into the BpiⅠ and AseⅠ sites of the pULcrRNA-UDrif plasmid, respectively, to obtain the recombinant vector, named pULcrRNA-UDrif-crRNArif.
[0083] Step 2: Construction of the rifamycin biosynthesis gene cluster deletion mutant in *Amylopectinobacter thaliana* U32 (Cas12a)
[0084] (1) Mix pULcrRNA-UDrif-crRNArif plasmid (1 μg) with Mediterranean amylopectinus U32 (Cas12a) competent cells (75 μL / tube) and transfer to a 2 mm electroporation cuvette pre-chilled on ice.
[0085] (2) The pULcrRNA-UDrif-crRNArif plasmid was introduced into competent cells of Amylopectinus thaliana U32 (Cas12a) by electroporation (parameters: 1795V, 25μF, 1000Ω). Immediately after electroporation, 800μL of Benedict's liquid medium was added to the electroporation cup, mixed by pipetting, and then transferred to a 1.5mL sterile EP tube. The tube was incubated in a shaker at 30℃ and 220rpm for more than 4 hours.
[0086] (3) The above incubation solution was centrifuged (8000 rpm, 2 min) to collect bacteria. After removing part of the supernatant, the remaining bacterial solution was spread on Benjamin's medium solid plate containing 50 μg / mL apramycin and placed in a 30℃ constant temperature incubator for about 7 days.
[0087] (4) Select single-clone transformants and first perform preliminary verification by colony PCR (preliminary verification primers: rifKOV1F / R, rifKOV2F / R). If there are positive clones, their PCR products are then further verified by sequencing.
[0088] (5) The correct transformants were passaged in Ben's liquid medium without apramycin antibiotic (2 generations). Then a small portion of the bacterial culture was taken from the second generation and diluted 200,000 times. The bacterial culture was then spread on Ben's solid medium plate without apramycin antibiotic and placed in an inverted incubator at 30°C for 4 days.
[0089] (6) Pick 6 clones from the Benn's solid medium plate, divide them into two, and transfer them to the Benn's solid medium plate and the Benn's solid medium plate containing apramycin, respectively. Place them in a constant temperature incubator at 30°C and invert them for 4 days.
[0090] (7) The clones that do not grow on Benjamin solid medium plates containing apramycin but grow on Benjamin solid medium plates are transferred to test tubes containing Benjamin liquid medium and cultured in a shaker incubator at 30°C and 220 rpm for 48 hours to obtain mutant clones that have lost the pULcrRNA-UDrif-crRNArif plasmid. Thus, the rifampicin biosynthesis gene cluster deletion mutant of Mediterranean pseudoamycin bacterium U32(Cas12a) was successfully constructed and named U32(Cas12a)Δrif.
[0091] Step 3: Deletion of the FnCas12a encoding gene
[0092] Since this embodiment uses Mediterranean amylopectinus U32 (Cas12a) containing the integrative plasmid pDZLCas12a as the starting strain for rif gene cluster deletion, in order to obtain cleaner chassis cells, it is necessary to further delete the integrative plasmid pDZLCas12a after successfully deleting the rif. Specifically: First, primers (AMED_0846-F and AMED_0846-R) for DNA recombination repair homologous arms containing the FnCas12a-encoding gene in the integrative plasmid pDZLCas12a were designed, along with oligonucleotide chains (pRT803crRNA-F and pRT803crRNA-R) corresponding to the crRNA targeting the FnCas12a-encoding gene. The DNA recombination repair homologous arms were then inserted into the NdeI restriction site of the pULcrRNA vector. After annealing, the oligonucleotide chain corresponding to the crRNA targeting the FnCas12a-encoding gene was inserted between the BpiI and AseI restriction sites. This resulted in the construction of a knockout vector targeting the integrative plasmid pDZLCas12a containing the FnCas12a-encoding gene, named pULcrRNA-UDcas12a-crRNAcas12a.
[0093] pULcrRNA-UDcas12a-crRNAcas12a was electroporated into the competent cells of *Amylopectinus thaliana* U32(Cas12a) Δrif, and mutants lacking the integration plasmid pDZLCas12a were screened. Then, pULcrRNA-UDcas12a-crRNAcas12a was plasmid-eliminated, ultimately yielding mutants lacking both rif and pDZLCas12a, thus obtaining *Amylopectinus thaliana* chassis cells U32 Δrif. The genome of *Amylopectinus thaliana* chassis cells U32 Δrif was validated by PCR using pRT803-KOV2-F and pRT803-KOV2-R. The validation results are as follows: Figure 1 As shown, U32Δrif was successfully constructed.
[0094] Step 4: Analysis of metabolites in U32Δrif fermentation broth
[0095] The fermentation broth of the mutant U32Δrif was analyzed by high performance liquid chromatography (HPLC), and the results are as follows: Figure 2 As shown, the secondary metabolites in the fermentation broth of U32Δrif were significantly reduced, while the fermentation broths of the control strains U32 and U32(Cas12a) were rich in secondary metabolites, including rifamycin S (an oxidation product of rifamycin SV).
[0096] The HPLC analysis conditions were as follows: The instrument was a Shimadzu LC-20AT. The analytical column was a Thermo Fisher Acclaim™ 120C18 (5μm, 4.6 x 250 mm). Phase A was pure water, and phase B was acetonitrile. The flow rates were: 0-3 min, 20% B; 3-6 min, 20%-40% B; 6-10 min, 40% B; 10-18 min, 40%-55% B; 18-21 min, 55%-85% B; 21-30 min, 85% B; 30-33 min, 85%-20% B; 33-35 min, 20% B.
[0097] Therefore, the Mediterranean pseudoamycete U32Δrif constructed in this invention has the potential to serve as a chassis strain, supplementing existing Streptomyces heterologous host chassis strains, and can be used to explore the rich gene cluster resources in other actinomycetes, especially pseudoamycete.
[0098] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for constructing a genetically defective Mediterranean pseudo-amycosis, characterized in that, include: Knock out the rifamycin biosynthesis gene cluster and the integration plasmid pDZLCas12a containing the FnCas12a encoding gene from the genome of the receptor *Amycium thalianae* U32 (Cas12a) to obtain *Amycium thalianae* with the aforementioned gene defect.
2. The method according to claim 1, characterized in that, The rifamycin biosynthesis gene cluster includes 43 genes: rifS, rifT, rif35, rif0, rifA, rifB, rifC, rifD, rifE, rifF, rif1, rifG, rifH, rifI, rifK, rifL, rifM, rifN, rifO, rif2, rifP, rifQ, rif3, rif4, rif5, rif6, rif7, rif8, rif9, rif10, rif11, rif17, rif18, rif19, rif20, rifR, rif13, rif14, rif15A, rif15B, rif16, rifJ, and rif36. The nucleotide sequence of the rifS is the sequence numbered AMED_0613 in Genebank CP002000; The nucleotide sequence of the rifT is the sequence numbered AMED_0614 in Genebank CP002000; The nucleotide sequence of rif35 is the sequence numbered AMED_0615 in Genebank CP002000; The nucleotide sequence of rif0 is the sequence numbered AMED_0616 in Genebank CP002000; The nucleotide sequence of rifA is the sequence numbered AMED_0617 in Genebank CP002000; The nucleotide sequence of rifB is the sequence numbered AMED_0618 in Genebank CP002000; The nucleotide sequence of rifC is the sequence numbered AMED_0619 in Genebank CP002000; The nucleotide sequence of rifD is the sequence numbered AMED_0620 in Genebank CP002000; The nucleotide sequence of the rifE is the sequence numbered AMED_0621 in Genebank CP002000; The nucleotide sequence of the rifF is the sequence numbered AMED_0622 in Genebank CP002000; The nucleotide sequence of rif1 is the sequence numbered AMED_0623 in Genebank CP002000; The nucleotide sequence of rifG is the sequence numbered AMED_0624 in Genebank CP002000; The nucleotide sequence of the rifH is the sequence numbered AMED_0625 in Genebank CP002000; The nucleotide sequence of the rifI is the sequence numbered AMED_0626 in Genebank CP002000; The nucleotide sequence of rifK is the sequence numbered AMED_0627 in Genebank CP002000; The nucleotide sequence of the rifL is the sequence numbered AMED_0628 in Genebank CP002000; The nucleotide sequence of rifM is the sequence numbered AMED_0629 in Genebank CP002000; The nucleotide sequence of the rifN is the sequence numbered AMED_0630 in Genebank CP002000; The nucleotide sequence of the rifO is the sequence numbered AMED_0631 in Genebank CP002000; The nucleotide sequence of rif2 is the sequence numbered AMED_0632 in Genebank CP002000; The nucleotide sequence of the rifP is the sequence numbered AMED_0633 in Genebank CP002000; The nucleotide sequence of the rifQ is the sequence numbered AMED_0634 in Genebank CP002000; The nucleotide sequence of the rif3 is the sequence numbered AMED_0635 in Genebank CP002000; The nucleotide sequence of the rif4 is the sequence numbered AMED_0636 in Genebank CP002000; The nucleotide sequence of the rif5 is the sequence numbered AMED_0637 in Genebank CP002000; The nucleotide sequence of rif6 is the sequence numbered AMED_0638 in Genebank CP002000; The nucleotide sequence of the rif7 is the sequence numbered AMED_0639 in Genebank CP002000; The nucleotide sequence of the rif8 is the sequence numbered AMED_0640 in Genebank CP002000; The nucleotide sequence of the rif9 is the sequence numbered AMED_0641 in Genebank CP002000; The nucleotide sequence of rif10 is the sequence numbered AMED_0642 in Genebank CP002000; The nucleotide sequence of rif11 is the sequence numbered AMED_0643 in Genebank CP002000; The nucleotide sequence of rif17 is the sequence numbered AMED_0644 in Genebank CP002000; The nucleotide sequence of rif18 is the sequence numbered AMED_0645 in Genebank CP002000; The nucleotide sequence of rif19 is the sequence numbered AMED_0646 in Genebank CP002000; The nucleotide sequence of rif20 is the sequence numbered AMED_0647 in Genebank CP002000; The nucleotide sequence of the rifR is the sequence numbered AMED_0648 in Genebank CP002000; The nucleotide sequence of rif13 is the sequence numbered AMED_0649 in Genebank CP002000; The nucleotide sequence of rif14 is the sequence numbered AMED_0650 in Genebank CP002000; The nucleotide sequence of rif15A is the sequence numbered AMED_0651 in Genebank CP002000; The nucleotide sequence of rif15B is the sequence numbered AMED_0652 in Genebank CP002000; The nucleotide sequence of rif16 is the sequence numbered AMED_0653 in Genebank CP002000; The nucleotide sequence of rifJ is the sequence numbered AMED_0654 in Genebank CP002000; The nucleotide sequence of rif36 is the sequence numbered AMED_0655 in Genebank CP002000.
3. The method according to claim 1, characterized in that, The FnCas12a encoding gene is the Cpf1 gene sequence in GenBank MF193599, and the protein sequence is the sequence in GenBank ASK09413.
1. The integration site of the FnCas12a encoding gene is located inside the gene numbered AMED_0846 in GenBank CP002000.
4. The genetically defective Mediterranean pseudoamycetes constructed by the method according to any one of claims 1-3.
5. The application of the genetically defective Mediterranean pseudoamycetes as described in claim 4 as a chassis strain in the identification of actinomycete biosynthetic gene clusters and / or the biosynthesis of target compounds.
6. A method for identifying biosynthetic gene clusters in actinomycetes, characterized in that, Includes the following steps: The target biosynthetic gene cluster derived from the target actinomycete is introduced into the gene-deficient Mediterranean pseudoamycete as described in claim 4, and heterologously expressed in the gene-deficient Mediterranean pseudoamycete. The heterologously expressed product is analyzed and its structure is determined to complete the identification of the actinomycete biosynthetic gene cluster.
7. The method according to claim 6, characterized in that, The target actinomycete is at least one of the genera *Amycium*, *Saccharomyces*, *Micromonospora*, and *Streptomyces*.
8. A method for heterologous synthesis of a target compound derived from actinomycetes, characterized in that, include: The target compound biosynthesis gene cluster derived from actinomycetes is introduced into the gene-deficient Mediterranean pseudoamycetes of claim 4, heterologously expressed in the gene-deficient Mediterranean pseudoamycetes, and the target compound is isolated from the culture product of the gene-deficient Mediterranean pseudoamycetes.
9. A knockout vector for knocking out the rifamycin biosynthesis gene cluster in the genome of the receptor *Amycium thalianae* U32 (Cas12a).
10. A knockout vector for the integration plasmid pDZLCas12a, which contains the FnCas12a encoding gene in the genome of the receptor *Amycium thalianae* U32 (Cas12a).
